An Exploratory Phase 2, 2-part, Randomized, Double-blind, Placebo-controlled Study With a Long-term, Open-label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Pro-gression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del